Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability

We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Arbutus Biopharma Corporation is among the best biotech stocks under $10 to buy.

TheFly reported on April 7 that Jefferies lowered its price target on ABUS from $7.00 to $5.50 while maintaining a Buy rating. The revision was driven by updated expectations around the outcome of Moderna’s appeal in ongoing litigation, which could influence a potential $1.3 billion payment tied to the case. The firm adjusted its probability assessment, increasing the likelihood of a Moderna win on appeal, which in turn reduced its valuation outlook for ABUS.

On March 23, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported its fourth-quarter and full-year 2025 financial results and provided a corporate update. The company highlighted its ongoing litigation-related developments, including a settlement agreement with Moderna and Genevant under which ABUS is entitled to a portion of a $950 million upfront payment expected in July 2026, along with potential eligibility for an additional $1.3 billion contingent on an appellate outcome.

Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability

It also noted continued legal proceedings involving its lipid nanoparticle intellectual property. For the year, the business reported revenue of $14.1 million, net loss of $33.5 million, cash and investments of $91.5 million, and reduced operating expenses driven by restructuring and cost optimization efforts focused on its clinical pipeline.

Arbutus Biopharma Corporation (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company focused on developing therapeutics for viral diseases. It is particularly known for its work in hepatitis B treatments, using RNA interference and lipid nanoparticle delivery technologies to target and suppress viral replication.

While we acknowledge the risk and potential of ABUS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABUS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest in According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.